Quest Diagnostics Beheer
Beheer criteriumcontroles 4/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Jim Davis
Algemeen directeur
US$12.7m
Totale compensatie
| Percentage CEO-salaris | 9.3% |
| Dienstverband CEO | 2yrs |
| Eigendom CEO | 0.07% |
| Management gemiddelde ambtstermijn | 4yrs |
| Gemiddelde ambtstermijn bestuur | 5.2yrs |
Recente managementupdates
Recent updates
Earnings Update: Quest Diagnostics Incorporated (NYSE:DGX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Oct 25
Quest Diagnostics: Organic Growth Leads To Q3 Earnings Beat
Oct 24Why Investors Shouldn't Be Surprised By Quest Diagnostics Incorporated's (NYSE:DGX) P/E
Oct 23Quest Diagnostics: The Better Half Of An Emerging Healthcare Duopoly
Oct 15These 4 Measures Indicate That Quest Diagnostics (NYSE:DGX) Is Using Debt Reasonably Well
Aug 30Should You Think About Buying Quest Diagnostics Incorporated (NYSE:DGX) Now?
Aug 12Quest Diagnostics: Beat Down After Beating Q2 Estimates
Jul 28The Price Is Right For Quest Diagnostics Incorporated (NYSE:DGX)
Jul 12Quest Diagnostics: On A Quest For Growth
Jul 12Quest Diagnostics (NYSE:DGX) Hasn't Managed To Accelerate Its Returns
May 14Quest Diagnostics: Let's Keep Waiting
May 08Results: Quest Diagnostics Incorporated Beat Earnings Expectations And Analysts Now Have New Forecasts
Apr 26We Think Quest Diagnostics (NYSE:DGX) Can Stay On Top Of Its Debt
Apr 23Unpleasant Surprises Could Be In Store For Quest Diagnostics Incorporated's (NYSE:DGX) Shares
Apr 02Quest Diagnostics (NYSE:DGX) Is Paying Out A Larger Dividend Than Last Year
Mar 15Quest Diagnostics (NYSE:DGX) Has Announced That It Will Be Increasing Its Dividend To $0.75
Feb 06Quest Diagnostics: Post-COVID Normalization Pretty Much Done
Feb 05Quest Diagnostics (NYSE:DGX) Seems To Use Debt Quite Sensibly
Jan 11Why We're Not Concerned About Quest Diagnostics Incorporated's (NYSE:DGX) Share Price
Dec 24Quest Diagnostics: Market Overreaction Creates Investment Opportunity
Dec 08Is There Now An Opportunity In Quest Diagnostics Incorporated (NYSE:DGX)?
Dec 06Quest Diagnostics' (NYSE:DGX) Returns Have Hit A Wall
Nov 18Quest Diagnostics: Moving Past Covid
Oct 25Here's Why Quest Diagnostics (NYSE:DGX) Can Manage Its Debt Responsibly
Sep 25What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Sep 04Quest Diagnostics: Q2 Earnings Reveal Promising Growth Trends Despite Dwindling COVID Testing Revenues
Aug 15Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
Aug 13Quest Diagnostics Incorporated (NYSE:DGX) Shares Could Be 46% Below Their Intrinsic Value Estimate
Jul 11Is Quest Diagnostics (NYSE:DGX) A Risky Investment?
Jun 09Quest Diagnostics: Healthier Diagnosis
May 30Is It Time To Consider Buying Quest Diagnostics Incorporated (NYSE:DGX)?
May 24Quest Diagnostics (NYSE:DGX) Has More To Do To Multiply In Value Going Forward
May 09An Intrinsic Calculation For Quest Diagnostics Incorporated (NYSE:DGX) Suggests It's 24% Undervalued
Mar 22What Does Quest Diagnostics Incorporated's (NYSE:DGX) Share Price Indicate?
Feb 19Why Quest Diagnostics Isn't A 'Buy', My Oh My
Feb 14Quest Diagnostics' (NYSE:DGX) Upcoming Dividend Will Be Larger Than Last Year's
Feb 05Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | US$838m |
| Jun 30 2024 | n/a | n/a | US$836m |
| Mar 31 2024 | n/a | n/a | US$842m |
| Dec 31 2023 | US$13m | US$1m | US$850m |
| Sep 30 2023 | n/a | n/a | US$759m |
| Jun 30 2023 | n/a | n/a | US$790m |
| Mar 31 2023 | n/a | n/a | US$789m |
| Dec 31 2022 | US$12m | US$806k | US$942m |
| Sep 30 2022 | n/a | n/a | US$1b |
| Jun 30 2022 | n/a | n/a | US$1b |
| Mar 31 2022 | n/a | n/a | US$2b |
| Dec 31 2021 | US$4m | US$625k | US$2b |
| Sep 30 2021 | n/a | n/a | US$2b |
| Jun 30 2021 | n/a | n/a | US$2b |
| Mar 31 2021 | n/a | n/a | US$2b |
| Dec 31 2020 | US$4m | US$577k | US$1b |
| Sep 30 2020 | n/a | n/a | US$1b |
| Jun 30 2020 | n/a | n/a | US$749m |
| Mar 31 2020 | n/a | n/a | US$771m |
| Dec 31 2019 | US$3m | US$590k | US$835m |
| Sep 30 2019 | n/a | n/a | US$709m |
| Jun 30 2019 | n/a | n/a | US$707m |
| Mar 31 2019 | n/a | n/a | US$720m |
| Dec 31 2018 | US$3m | US$590k | US$733m |
| Sep 30 2018 | n/a | n/a | US$860m |
| Jun 30 2018 | n/a | n/a | US$808m |
| Mar 31 2018 | n/a | n/a | US$782m |
| Dec 31 2017 | US$3m | US$590k | US$769m |
Compensatie versus markt: De totale vergoeding ($USD 12.67M ) Jim } is ongeveer het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 12.87M ).
Compensatie versus inkomsten: De vergoeding van Jim is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Jim Davis (61 yo)
2yrs
Tenure
US$12,673,834
Compensatie
Mr. James E. Davis, also known as Jim, serves as Chief Executive Officer and President at Quest Diagnostics Incorporated since November 1, 2022 and serves as its Director since November 2022. He served as...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 2yrs | US$12.67m | 0.067% $ 11.6m | |
| Executive VP & CFO | 2.3yrs | US$3.98m | 0.016% $ 2.7m | |
| Senior VP & General Counsel | 25.3yrs | US$2.25m | 0.039% $ 6.8m | |
| Executive Vice President of Regional Businesses | no data | US$3.16m | 0.058% $ 10.1m | |
| Senior Vice President of Clinical Solutions | 2.3yrs | US$2.02m | 0.010% $ 1.8m | |
| Senior VP | 5.6yrs | geen gegevens | 0.032% $ 5.5m | |
| Senior VP | less than a year | geen gegevens | geen gegevens | |
| Vice President of Investor Relations | no data | geen gegevens | geen gegevens | |
| Senior VP & Chief Compliance Officer | 2.1yrs | geen gegevens | geen gegevens | |
| Senior VP & Chief Communications Officer | 28yrs | geen gegevens | geen gegevens | |
| Senior VP & Chief Human Resources Officer | 6.8yrs | geen gegevens | geen gegevens | |
| Senior Vice President of Strategy | 8.8yrs | geen gegevens | geen gegevens |
4.0yrs
Gemiddelde duur
61yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van DGX wordt beschouwd als ervaren (gemiddelde ambtstermijn 4 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Chairman | 2yrs | US$12.67m | 0.067% $ 11.6m | |
| Independent Director | 10.8yrs | US$315.44k | 0.022% $ 3.9m | |
| Director | less than a year | geen gegevens | geen gegevens | |
| Lead Independent Director | 12.9yrs | US$345.94k | geen gegevens | |
| Independent Director | 19.9yrs | US$342.12k | geen gegevens | |
| Independent Director | 5.8yrs | US$312.33k | 0.0026% $ 445.5k | |
| Independent Director | 10.3yrs | US$315.73k | 0.016% $ 2.8m | |
| Independent Director | 4.7yrs | US$300.44k | geen gegevens | |
| Independent Director | 3.3yrs | US$300.44k | geen gegevens | |
| Independent Director | 1.5yrs | US$280.41k | geen gegevens |
5.2yrs
Gemiddelde duur
65yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van DGX wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.2 jaar).